Azithromycin Reduction to Reach Elimination of Trachoma
减少阿奇霉素以消除沙眼
基本信息
- 批准号:10397057
- 负责人:
- 金额:$ 76.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AgeAntibioticsAreaAzithromycinBlindnessChildChlamydiaChlamydia InfectionsChlamydia trachomatisClinicalCommunitiesConfidence IntervalsCountryDataDecision MakingDiagnostic testsDropsEarly treatmentEuropeFundingGambiaGhanaGoalsGuidelinesHygieneIndividualInfectionInflammationInterventionLaosLeadLow PrevalenceMacrolidesMeasuresMexicoNepalNigerPrevalencePublic HealthRandomizedRandomized Controlled TrialsRecrudescencesResidual stateResourcesSanitationSavingsSeroprevalencesSurveysTestingTrachomaUgandaUveitisWaterWorld Health Organizationbasediscontinuation trialisoniazidmarkov modelpopulation basedprogramsrandomized placebo controlled trialresponseserological markertooltransmission processtreatment response
项目摘要
PROJECT SUMMARY/ABSTRACT
Annual mass azithromycin distribution dramatically reduces the prevalence of the ocular strains of Chlamydia
trachomatis that lead to blinding trachoma. Current World Health Organization guidelines indicate that annual
mass azithromycin distribution should be continued until district-level prevalence of the clinical sign of
trachoma, trachomatous inflammation-follicular (TF), drops below 5%. However, TF does not correlate well
with infection after multiple rounds of azithromycin treatment. Specifically, any decrease in TF lags well behind
the decrease in infection. Thus the TF threshold may lead to overuse of antibiotics and depletion of scarce
resources. Here, we propose a community randomized controlled trial and diagnostic test study to evaluate
whether 1) azithromycin distribution can be discontinued in communities with TF prevalence up to 20%, and 2)
alternative indicators of trachoma transmission can better measure true infection. We anticipate that results will
provide evidence to support discontinuation of azithromycin treatment earlier, and evidence of that true local
elimination of infection can be achieved, altering the goal of the trachoma program from control to eradication.
项目总结/摘要
每年大规模分发阿奇霉素可显著降低衣原体眼部菌株的患病率
导致失明的沙眼。目前世界卫生组织的指导方针表明,
应继续大规模分发阿奇霉素,直到地区一级的临床症状普遍存在,
沙眼,即沙眼性炎症-滤泡(TF),下降到5%以下。然而,TF没有很好地相关
阿奇霉素治疗后感染具体来说,TF的任何下降都远远滞后于
减少感染。因此,TF阈值可能会导致抗生素的过度使用和稀缺资源的耗尽
资源在这里,我们提出了一个社区随机对照试验和诊断测试研究,以评估
1)在TF患病率高达20%的社区是否可以停止阿奇霉素的销售,以及2)
沙眼传播的替代指标可以更好地衡量真正的感染。我们预计,结果将
提供证据以支持更早停止阿奇霉素治疗,并提供证据表明,
消除感染是可以实现的,将沙眼项目的目标从控制改为根除。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS M LIETMAN其他文献
THOMAS M LIETMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS M LIETMAN', 18)}}的其他基金
Azithromycin Reduction to Reach Elimination of Trachoma
减少阿奇霉素以消除沙眼
- 批准号:
10439385 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
Azithromycin Reduction to Reach Elimination of Trachoma
减少阿奇霉素以消除沙眼
- 批准号:
10616840 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
UCSF-Proctor Clinician Vision Scholars K12 Program
UCSF-Proctor 临床医生视力学者 K12 计划
- 批准号:
10610924 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
UCSF-Proctor Clinician Vision Scholars K12 Program
UCSF-Proctor 临床医生视力学者 K12 计划
- 批准号:
10409646 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
Azithromycin Reduction to Reach Elimination of Trachoma
减少阿奇霉素以消除沙眼
- 批准号:
10907941 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
Azithromycin Reduction to Reach Elimination of Trachoma
减少阿奇霉素以消除沙眼
- 批准号:
10618166 - 财政年份:2020
- 资助金额:
$ 76.63万 - 项目类别:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
类固醇和交联治疗溃疡 (SCUT II)
- 批准号:
10397960 - 财政年份:2019
- 资助金额:
$ 76.63万 - 项目类别:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
类固醇和交联治疗溃疡 (SCUT II)
- 批准号:
10457913 - 财政年份:2019
- 资助金额:
$ 76.63万 - 项目类别:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
类固醇和交联治疗溃疡 (SCUT II)
- 批准号:
10222699 - 财政年份:2019
- 资助金额:
$ 76.63万 - 项目类别:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
类固醇和交联治疗溃疡 (SCUT II)
- 批准号:
10666415 - 财政年份:2019
- 资助金额:
$ 76.63万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Studentship
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Research Grant
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 76.63万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 76.63万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 76.63万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 76.63万 - 项目类别:
Studentship














{{item.name}}会员




